国际眼科网 - 眼科专家交流中心!

国际眼科网

点击这里了解更多三焦点人工晶体信息
当前位置: 首页 > 学术论文 >

玻璃体注射Bevacizumab治疗26例Ⅰ区早产儿视网膜病变

时间:2016-07-22 10:40来源:未知 作者:国际眼科网编辑 点击:
玻璃体注射Bevacizumab治疗26例Ⅰ区早产儿视网膜病变 Clinical report of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity in Zone Ⅰ 投稿时间: 2016-02-23 最后修改时间: 2016-06-13 推荐文章 收藏文章 打印页面 DOI: 10.3980/
玻璃体注射Bevacizumab治疗26例Ⅰ区早产儿视网膜病变
Clinical report of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity in Zone Ⅰ
投稿时间: 2016-02-23  最后修改时间: 2016-06-13
推荐文章  收藏文章  打印页面
DOI:10.3980/j.issn.1672-5123.2016.7.42
关键词:  阈值期早产儿视网膜病变  阈值前期早产儿视网膜病变  急性后极部早产儿视网膜病变  玻璃体注射术  bevacizumab
Key Words:  threshold retinopathy of prematurity  pre-threshold retinopathy of prematurity  acute posterior retinopathy of prematurity  intravitreal injection  bevacizumab
基金项目:广州市卫生科技项目(No.201102A212032)
Fund Project:Program of Guangzhou Medical Technology(No.201102A212032)
           
作者 单位
陈锋 中国广东省广州市妇女儿童医疗中心眼科
项道满 中国广东省广州市妇女儿童医疗中心眼科
王建勋 中国广东省广州市妇女儿童医疗中心眼科
刘恬 中国广东省广州市妇女儿童医疗中心眼科
摘要点击次数: 9
全文下载次数: 11
摘要:
      目的:评价玻璃体注射bevacizumab治疗26例Ⅰ区早产儿视网膜病变(retinopathy of prematurity,ROP)的治疗效果。

 

     方法:通过回顾性研究,对2013-09/2014-10确诊为Ⅰ区阈值期ROP并行玻璃体注射bevacizumab治疗的26例患儿分三组(阈值前期Ⅰ型ROP、阈值期ROP、急进型后极部早产儿视网膜病变-APROP),进行术后效果分析比较。

 

     结果:治疗Ⅰ区高危性阈值期ROP患儿26例52眼。其中阈值前期Ⅰ型ROP 3例6眼,阈值期ROP 15例30眼,APROP 8例16眼。治疗阈值期Ⅰ型ROP、阈值期ROP和APROP的一次手术治愈率分别为100%(6/6)、60%(18/30)和75%(12/16),三组之间手术治愈率无统计学差异(P>0.05)。

 

     结论:玻璃体腔内注射bevacizumab治疗Ⅰ区ROP的临床疗效明确,比传统光凝术治疗具有一定优越性,可作为I区ROP的一线治疗方法。

Abstract:
      AIM:To investigate the clinical effects of intravitreal Bevacizumab for 26 cases with retinopathy of prematurity(ROP)in Zone Ⅰ.

 

     METHODS:A retrospective study. Totally 26 ROP infants between September 2013 and October 2014 diagnosed as high-risk ROP in Zone Ⅰ had been treated with intravitreal bevacizumab. They were divided into three groups, pre-threshold ROP, threshold ROP and acute posterior ROP(APROP). Postoperative effects were compared.

 

     RESULTS:There were 26 infants(52 eyes)diagnosed as ROP in Zone Ⅰ, including 3 infants( 6 eyes)with pre-threshold ROP, 15 infants(30 eyes)with threshold ROP and 8 infants(16 eyes)with APROP. The first operation recovery rate of three groups respectively were 100%(6/6), 60%(18/30)and 75%(12/16), which were not significantly different(P>0.05).

 

     CONCLUSION:Intravitreal bevacizumab for ROP in Zone Ⅰ seems effective and has some advantages over conventional laser treatment, which could be first line treatment for high-risk ROP in Zone Ⅰ.

Citation Html:
查看全文  查看/发表评论  下载PDF阅读器

(责任编辑:国际眼科网编辑)
顶一下
(0)
0%
踩一下
(0)
0%
------分隔线----------------------------